Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 801–900 of 1,000
Yokoyama, H., Yano, R., Aoki, E., Kato, H., & Araki, T. (2008) · Metabolic Brain Disease · doi:10.1007/s11011-008-9096-3 · Cited by 24
“Parkinson’s disease (PD) is a progressive and age-related neurodegenerative disease characterized by degeneration of dopaminergic neurons originating in the substantia nigra pars compacta and projecting to the dorsal striatum ( Hirsh et al. 1988 ).”
BackgroundHerrero, M. T., Hirsch, É. C., Javoy-Agid, F., Obeso, J. A., & Agid, Y. (1993) · Brain Research · doi:10.1016/0006-8993(93)90088-5 · Cited by 21
Self-citationProteomics as a new paradigm to tackle Parkinson’s disease research challenges
Licker, V., & Burkhard, P. R. (2014) · Translational Proteomics · doi:10.1016/j.trprot.2014.08.001 · Cited by 22
Subtle Cardiovascular Dysfunction in the Unilateral 6-Hydroxydopamine-Lesioned Rat
Slack, K., Billing, R., Matthews, S. T., Allbutt, H. N., Einstein, R., & Henderson, J. M. (2010) · Parkinson s Disease · doi:10.4061/2010/427810 · Cited by 24
“Since there is no striatal neurodegeneration in PD and the VTA (A10) is not the major site of dopaminergic cell loss in patients [33], targeting the MFB produces an animal model more likely to mimic nigral degeneration and accompanying motor symptoms of PD than models targeting either VTA or the striatum.”
BackgroundTrasplante celular y terapia regenerativa con células madre
Prósper, F., Gavira, J. J., Herreros, J. M., Rábago, G., Luquín, M. R., Moreno, J., Robles, J. E., & Redondo, P. (2006) · Anales del Sistema Sanitario de Navarra · doi:10.4321/s1137-66272006000400018 · Cited by 45
The midbrain dopaminergic cell groups in the baboon papio ursinus
McRitchie, D. A., Cartwright, H., Pond, S. M., der Schyf, C. J. V., Castagnoli, N., van der Nest, D. G., & Halliday, G. M. (1998) · Brain Research Bulletin · doi:10.1016/s0361-9230(98)00128-2 · Cited by 25
Glia Protects Neurons against Extracellular Human Neuromelanin
Depboylu, C., Matusch, A., Tribl, F., Zoriy, M. V., Michel, P. P., Riederer, P. F., Gerlach, M., Becker, S., Oertel, W. H., & Höglinger, G. U. (2007) · Neurodegenerative Diseases · doi:10.1159/000101846 · Cited by 22
“Within the SN, a significantly lower neuromelanin content of the remaining catecholaminergic neurons is observed in PD, and the neuromelanin content is inversely correlated to disease state [”
BackgroundTopographical organization of projections from the subiculum to the hypothalamus in the rat
Kishi, T., Tsumori, T., Ono, K., Yokota, S., Ishino, H., & Yasui, Y. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000403)419:2<205::aid-cne5>3.0.co;2-0 · Cited by 117
Self-citationNeurotransmitters’ white matter mapping unveils the neurochemical fingerprints of stroke
Alves, P. N., Nozais, V., Hansen, J. Y., Corbetta, M., Nachev, P., Martins, I. P., & de Schotten, M. T. (2025) · Nature Communications · doi:10.1038/s41467-025-57680-2 · Cited by 24
Neuromelanin and selective neuronal vulnerability to Parkinson’s disease
Filimontseva, A., Fu, Y., Vila, M., & Halliday, G. M. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.04.005 · Cited by 28
“However, other catecholamine-producing neurons with little or no pigmentation tend to be spared until the later stages of PD [4,5].”
Jovanović, P., Wang, Y., Vit, J., Novinbakht, E., Morones, N., Hogg, E. J., Tagliati, M., & Riera, C. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263074 · Cited by 24
“DA neuronal death is linked to motor impairments including bradykinesia, tremor, muscular rigidity and postural instability [1, 2].”
BackgroundRavenhill, S. M., Evans, A. H., & Crewther, S. G. (2023) · Antioxidants · doi:10.3390/antiox12051117 · Cited by 25
“Results from immunohistochemical analysis in rats and human imaging studies, which allow an accurate quantification of dopaminergic neuronal cell densities, reveal that similar dopaminergic cell losses also occur within the A8 mid-brain retrorubral (31% loss) and A10 ventral tegmentum areas (VTA) (55% loss) [5,21,82],…”
BackgroundLittrell, O. M., Granholm, A., Gerhardt, G. A., & Boger, H. A. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.022 · Cited by 20
“Outline contours drawn for SN cell counts included areas containing Please cite this article as: Littrell OM, et al, Glial cell-line derived neurotro nigrostriatal dopamine deficits in 12-month-old mice ..., Pharmacol Bioc E D P R O O F predominately TH-labeled dopaminergic neurons (substantia nigra pars compacta (SNc…”
InfluentialGenetic dissection of midbrain dopamine neuron development in vivo
Ellisor, D., Rieser, C. J., Voelcker, B., Machan, J. T., & Zervas, M. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.09.019 · Cited by 22
“Parkinson’s disease is typically attributed to SNc MbDA neuron loss (Parent, 1996), but is often accompanied by VTA loss (Damier et al., 1999; Hirsch et al., 1988; Uhl et al., 1985).”
Grow, D. A., Simmons, D. V., Gómez, J. A., Wanat, M. J., McCarrey, J. R., Paladini, C. A., & Navara, C. S. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0073 · Cited by 21
Ling, S., Bao, A., & Swaab, D. (2017) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_125 · Cited by 18
Multimodal assessment of nigrosomal degeneration in Parkinson's disease
Langley, J. A., Huddleston, D. E., Crosson, B., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.021 · Cited by 20
“These results accord with histological studies showing the greatest amount of PD-related neuronal loss in SNpc occurs in the lateral-ventral tier of SNpc [2, 5, 6].”
BackgroundResultFbxo7 and Pink1 play a reciprocal role in regulating their protein levels
Huang, T., Fang, L., He, R., Weng, H., Chen, X., Ye, Q., & Qu, D. (2020) · Aging · doi:10.18632/aging.202236 · Cited by 19
“Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease after Alzheimer’s disease, characterized by tremor, rigidity and bradykinesia due to dopaminergic (DA) loss in substantial nigra pars compacta (SNc) [1, 2].”
BackgroundHeterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain
Tong, J., Furukawa, Y., Sherwin, A. L., Hornykiewicz, O., & Kish, S. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.017 · Cited by 19
“Thus, studies of different characteristics amongst dopamine cell bodies such as neuromelanin (Gibb and Lees, 1991; Hirsch et al., 1988; Kastner et al., 1992), calcium stress (Chan et al., 2007; Damier et al., 1999; Gibb, 1992; Yamada et al., 1990), the dopamine transporter (Gonzalez-Hernandez et…”
BackgroundHimeda, T., Kadoguchi, N., Kamiyama, Y., Kato, H., Maegawa, H., & Araki, T. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.09.014 · Cited by 23
Model neuromelanins as antioxidative agents during lipid peroxidation
Wilczok, T., Stȩpień, K. B., Dzierżęga‐Lęcznar, A., Zajdel, A., & Wilczok, A. (1999) · Neurotoxicity Research · doi:10.1007/bf03033277 · Cited by 20
Chemical architecture of the basal ganglia
Graybiel, A. M., & Penney, J. B. (1999) · Handbook of chemical neuroanatomy · doi:10.1016/s0924-8196(99)80025-6 · Cited by 20
Self-citationMoukhles, H., Amalric, M., Nieoullon, A., et al. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90008-6 · Cited by 20
Computer Methods in Nuclei Cartography
Hirsch, É. C., Lejeune, O., Colliot, G., et al. (1992) · Methods in neurosciences · doi:10.1016/b978-0-12-185269-6.50010-2 · Cited by 20
García-Gómara, M., Legarra-Marcos, N., Serena, M., Rojas-de-Miguel, E., Espelosin, M., Marcilla, I., Pérez‐Mediavilla, A., Luquín, M. R., Lanciego, J. L., Burrell, M. A., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.049 · Cited by 21
Neuromelanin formation exacerbates HAA-induced mitochondrial toxicity and mitophagy impairments
Lawana, V., Um, S. Y., Foguth, R. M., & Cannon, J. R. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.10.005 · Cited by 18
“Nevertheless, increasing evidence indicates that neurons with high neuromelanin content are more susceptible to death (Gibb, 1992; Hasegawa, 2010; Hirsch et al., 1988; Mann and Yates, 1983).”
BackgroundLin, C., Knoop, L., Frigerio, I., Bol, J. G. J. M., Rozemüller, A. J. M., Berendse, H. W., Pouwels, P. J. W., van de Berg, W. D. J., & Jonkman, L. E. (2023) · Movement Disorders · doi:10.1002/mds.29510 · Cited by 20
“However, dopaminergic neurons within the VTA are relatively preserved in PD.(39-43) In contrast, the number of dopaminergic neurons within the SN, particularly the medial SN, are reduced in both PD and PDD.”
BackgroundPetrosyan, T., Gevorkyan, O. V., Chavushyan, V. A., Meliksetyan, I. B., Hovsepyan, A. S., & Manvelyan, L. R. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.001 · Cited by 21
Jgamadze, D., Bergen, J., Stone, D., Jang, J., Schaffer, D. V., Isacoff, E. Y., & Pautot, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030293 · Cited by 20
“Dysfunctions in synaptic transmission and degeneration of specific classes of neurons are at the origin of many neurological disorders [1,2,3,4,5,6,7,8].”
Pitx3 and En1 determine the size and molecular programming of the dopaminergic neuronal pool
Kouwenhoven, W. M., von Oerthel, L., & Smidt, M. P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182421 · Cited by 21
“Interestingly, post-mortem tissue of PD patients revealed that mdDA neurons of the SNc are more vulnerable to cell loss (~80% of the SNc neurons are lost), while the mdDA neurons of the VTA are spared more (~50% loss) [1,2].”
BackgroundSchmidt, F., Douaron, G. L., Champy, P., Amar, M., Séon‐Méniel, B., Raisman‐Vozari, R., & Figadère, B. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.067 · Cited by 19
Wang, T., Liu, Y., Yang, N., Ji, C., Chan, P., & Zuo, P. (2012) · PubMed Central · doi:10.3969/j.issn.1673-5374.2012.14.006 · Cited by 21
“Parkinson’s disease (PD) is a progressive and age-related neurodegenerative disease characterized by degeneration of dopaminergic neurons originating in the substantia nigra pars compacta and projecting to the dorsal striatum([1]).”
BackgroundGenetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain
Ren, Y., Nishida, Y., Yoshimi, K., Yasuda, T., Jishage, K., Uchihara, T., Yokota, T., Mizuno, Y., & Mochizuki, H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03994.x · Cited by 21
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by degeneration of dopaminergic neurons localized in the substantia nigra pars compacta (SNpc) and the striatum (Hirsch et al. 1988).”
BackgroundIto, S., Napolitano, A., Sarna, T., & Wakamatsu, K. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02574-6 · Cited by 18
“In contrast, NM decreases in PD, in which DA neurons containing NM preferentially degenerate in parallel with a marked reduction in NM in the SN (Hirsch et al. 1988).”
BackgroundHovakimyan, M., Haas, S. J.-P., Schmitt, O., Gerber, B., Wree, A., & Andressen, C. (2006) · Journal of Anatomy · doi:10.1111/j.1469-7580.2006.00654.x · Cited by 18
“Parkinson’s disease (PD) is a slowly progressive degenerative disorder of the central nervous system (CNS), caused by the chronic loss of dopaminergic (DAergic) neurons in the substantia nigra and subsequently depletion of dopamine in the striatum, the main projection area of the substantia nigra (Bernheimer et al. 19…”
BackgroundMarques, N. F., de Castro, A. A., Mancini, G., da Rocha, F. L. N., Santos, A. R. S., Prediger, R. D., Bem, A. F. D., & Tasca, C. I. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9840-8 · Cited by 18
“…a debilitating disease characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) with the presence of eosinophilic, intracytoplasmic, proteinaceous inclusions termed as Lewy bodies and dystrophic Lewy neurites in surviving neurons (Hirsch et al. 1988).”
Farahi, A., Hammani, H., Kajai, A., Lahrich, S., Bakasse, M., & Mhammedi, M. A. E. (2019) · International Journal of Environmental & Analytical Chemistry · doi:10.1080/03067319.2019.1636043 · Cited by 19
Neuroprotective activities of catalpol on MPP+/MPTP-induced neurotoxicity
Jiang, B., Zhang, H., Bi, J., et al. (2008) · Neurological Research · doi:10.1179/174313208x289543 · Cited by 18
Thong, P. S. P., Watt, F., Ponraj, D., Leong, S. K., He, Y., & Lee, T. K. Y. (1999) · Nuclear Instruments and Methods in Physics Research Section B Beam Interactions with Materials and Atoms · doi:10.1016/s0168-583x(99)00390-0 · Cited by 18
Chapter 5 The substantia nigra and its relations with the striatum in the monkey
Langer, L. F., Jiménez-Castellanos, J., & Graybiel, A. M. (1991) · Progress in brain research · doi:10.1016/s0079-6123(08)63048-4 · Cited by 17
Self-citationImaging in cell-based therapy for neurodegenerative diseases
Kirik, D., Breysse, N., Björklund, T., Besret, L., & Hantraye, P. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1909-6 · Cited by 19
“Post-mortem analysis of brains from PD patients revealed that specific subpopulations of dopaminergic neurons are more vulnerable [21, 22], and that the parkinsonian neurodegeneration is not simply an accelerated form of cell loss that could be seen due to normal aging [23, 24].”
Obata, T., & Yamanaka, Y. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02203-x · Cited by 20
Chemiexcitation: Mammalian Photochemistry in the Dark†
Brash, D. E., & Goncalves, L. C. P. (2023) · Photochemistry and Photobiology · doi:10.1111/php.13781 · Cited by 16
Mondal, R., Mukherjee, N., & Ahmed, S. F. (2025) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2025.114449 · Cited by 19
Dutta, M. S., Mahapatra, P., Ghosh, A., & Basu, S. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10232-4 · Cited by 20
Sussulini, A., Matusch, A., Klietz, M., Bauer, A., Depboylu, C., & Becker, J. S. (2012) · Biomedical Spectroscopy and Imaging · doi:10.3233/bsi-2012-0011 · Cited by 17
“In stage III, key motor symptoms of PD are caused by the loss of dopamine levels in the striatum due to progressive degeneration of neuromelanin-containing neurons in the substantia nigra (SN) [26].”
Harrison, I. F., Anis, H. K., & Dexter, D. T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.12.052 · Cited by 17
Estimates of Intracellular Dopamine in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Sackner‐Bernstein, J. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212715 · Cited by 23
Systems Biology of Parkinson's Disease
Wellstead, P. E., & Cloutier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3411-5 · Cited by 17
Macreadie, I. G., Bartone, N., & Sparrow, L. G. (2010) · SLAS DISCOVERY · doi:10.1177/1087057109358920 · Cited by 17
Hall, H., Cuellar-Baena, S., Dahlberg, C., in’t Zandt, R., Denisov, V., & Kirik, D. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2011_166 · Cited by 17
“This leads to a severe dopamine depletion at the striatal level, responsible for most of the motor disturbances (Hirsch et al. 1988; Fearnley and Lees 1991; Nyberg et al. 1983).”
BackgroundHow to judge animal models of Parkinson’s disease in terms of neuroprotection
Hirsch, É. C. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_39 · Cited by 17
“Yet, other dopaminergic neurons are also affected in PD albeit to a lesser extent (Hirsch et al., 1988).”
BackgroundSengstock, G. J., Zawia, N. H., Olanow, C. W., Dunn, A. J., & Arendash, G. W. (1997) · Biological Trace Element Research · doi:10.1007/bf02917470 · Cited by 17
“In PD, there are indications that Fe within the SNc may be in a more reactive form since nearly all NS-DA neurons contain neuromelanin ( 30 ), a breakdown product of”
BackgroundYeap, Y. J., Tng, T. J. W., Lee, M. J., Goh, M., & Lim, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032523 · Cited by 23
“In PD, progressive neurodegeneration of A9 DA neurons occurs [6], whereas those in the VTA of the SN are largely unaffected [7,8].”
BackgroundMedeiros, D. D. C., Plewnia, C., Mendes, R. A. V., Pisanò, C. A., Boi, L., Moraes, M. F. D., Lopes‐Aguiar, C., & Fisone, G. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102536 · Cited by 17
“…it is worth mentioning that even though in PD patients the mesolimbic pathway is relatively spared in comparison to the nigrostriatal system (Hirsch et al., 1988; Kish et al., 1988), neuronal loss in the VTA has been proposed to contribute to PD non-motor symptoms, including cognitive and…”
Sonia, J., Kumara, B. N., Pinto, K. J., Hashim, A., Priya, E. S., Kalpana, B., Thomas, R., & Prasad, K. S. (2024) · Talanta · doi:10.1016/j.talanta.2024.125940 · Cited by 19
Longitudinal neuromelanin changes in prodromal and early Parkinson’s disease in humans and rat model
Pérot, J., Ruze, A., Gaurav, R., Rebbah, S., Cadin, C., Troter, A. L., Soustelle, L., Mouton, L., Valabrègue, R., Parent, A., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf204 · Cited by 18
Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons
Kim, S. T., Kim, E., Choi, J. H., Son, H. J., Ji, I. J., JOH, T. H., Chung, S. J., & Hwang, O. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.09.014 · Cited by 16
Decomposition of abnormal free locomotor behavior in a rat model of Parkinson's disease
Grieb, B., von Nicolai, C., Engler, G., Sharott, A., Papageorgiou, I. E., Hamel, W., Engel, A. K., & Moll, C. K. E. (2013) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2013.00095 · Cited by 17
“It is worth mentioning that our stereological results were similar to cell-loss estimates of 40–50% in the VTA described in human postmortem studies (Uhl et al., 1985; Hirsch et al., 1988; Dymecki et al., 1996; McRitchie et al., 1997; Thobois et al., 2010).”
ResultGanapathy, K., Datta, I., & Bhonde, R. R. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1367-3 · Cited by 17
Senkevich, K. A., Kopytova, A. E., Usenko, T. S., Emelyanov, A., & Pchelina, S. (2021) · Acta Naturae · doi:10.32607/actanaturae.11031 · Cited by 21
PARK13 regulates PINK1 and subcellular relocation patterns under oxidative stress in neurons
Patil, K. S., Basak, I., Lee, S., Abdullah, R., Larsen, J. P., & Møller, S. G. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23396 · Cited by 17
“Parkinson’s disease (PD) is the second-most common neurodegenerative disorder associated, with selective degeneration of dopamine-producing neurons in the substantia nigra pars compacta and widespread alterations in other brain regions (Hirsch et al., 1988; Braak et al., 2003).”
BackgroundPasbakhsh, P., Omidi, N., Mehrannia, K., Sobhani, A., Kashani, I. R., Abbasi, M., & Valeshabad, A. K. (2008) · PubMed · Cited by 16
Gadolinium-based MRI contrast agent for the detection of tyrosinase
Seo, H., & Clark, H. A. (2019) · The Analyst · doi:10.1039/c9an02213a · Cited by 16
Kurosaki, R., Muramatsu, Y., Imai, Y., Kato, H., & Araki, T. (2004) · Neurological Research · doi:10.1179/016164104225015949 · Cited by 16
Activation of diacylglycerol kinase by carbachol in guinea pig taenia coli
Nobe, K., Ohata, H., & Momose, K. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90499-5 · Cited by 16
Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons
Aimi, Y., & McGeer, P. L. (1996) · Parkinsonism & Related Disorders · doi:10.1016/1353-8020(96)00004-1 · Cited by 17
Clinical Investigation of Tyrosinase Inhibitors: Past, Present, and Future
Wang, Y. Y., Jiang, R., Xiong, B., Zhu, J., Sang, J., Li, H., Chen, C., Xu, Z., Zhang, W., Chen, Y., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70113 · Cited by 19
“In PD, there is a selective degeneration of neuromelanin ‐ containing neurons, especially substantia nigra dopaminergic neurons (Hirsch et al. 1988).”
Pagliaccio, D., Wengler, K., Durham, K., Fontaine, M., Rueppel, M., Becker, H. C., Bilek, E. L., Pieper, S., Risdon, C., Horga, G., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02105-z · Cited by 15
“Several studies have shown sizeable decreases in SNpc neuromelanin-MRI signal in Parkinson ’ s disease [35 – 45], consistent with the underlying degeneration of SNpc dopamine neurons [46].”
Yan, Y., Zhang, M., Ren, W., Zheng, X., & Chang, Y. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16296 · Cited by 15
“…with an age-matched control group, the NM-MRI signal in the SNpc of patients with PD is reliably reduced, aligning with the degeneration of NM-positive SNpc dopamine cells (Hirsch et al., 1988) and the reduction of NM concentration in SN tissues after death in patients with PD (Zecca et al., 2002).”
BackgroundCarnosic acid protects non-alcoholic fatty liver-induced dopaminergic neuron injury in rats
Xu, T., Zhou, J., Zhu, J., Zhang, S., Zhang, N., Zhao, Y., Ding, C., Shi, X., & Yao, J. (2016) · Metabolic Brain Disease · doi:10.1007/s11011-016-9941-8 · Cited by 19
Glass, T. J., Kelm‐Nelson, C. A., Szot, J. C., Lake, J. M., Connor, N. P., & Ciucci, M. R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240366 · Cited by 15
Salzman, G., Kim, J. T., Horga, G., & Wengler, K. (2021) · Journal of Visualized Experiments · doi:10.3791/62493 · Cited by 20
Computer-Aided Classification Framework of Parkinsonian Disorders Using 11C-CFT PET Imaging
Xu, J., Xu, Q., Liu, S., Li, L., Li, L., Yen, T., Wu, J., Wang, J., Zuo, C., Wu, P., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.792951 · Cited by 15
“These results may stem from a similar extent of midbrain dopaminergic neuron loss across different PDs, although published data in the field remain inconclusive (Hirsch et al., 1988; Fearnley and Lees, 1991; Martin-Bastida et al., 2017).”
ResultNeurobiological and Pharmacological Perspectives of D3 Receptors in Parkinson’s Disease
Chagraoui, A., Giovanni, G. D., & Deurwaerdère, P. D. (2022) · Biomolecules · doi:10.3390/biom12020243 · Cited by 19
“Thus, DA cell groups in the nigra exhibit different expressions of calretinin, calbindin [43], and cholecystokinin [44], and also different accumulations of melanin [45–47].”
Nanoparticles-based delivery system and its potentials in treating central nervous system disorders
Liu, T., Xie, Q., Dong, Z., & Peng, Q. (2022) · Nanotechnology · doi:10.1088/1361-6528/ac85f3 · Cited by 16
Plum, S., Steinbach, S., Abel, L., Marcus, K., Helling, S., & May, C. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400030 · Cited by 20
“In individuals with PD, a pallor of the black-brownish color in the substantia nigra can be observed due to the loss of dopaminergic NM-containing neurons [203, 204].”
Chemical state imaging of iron in nerve cells from a patient with Parkinsonism-dementia complex
Ide‐Ektessabi, A., Fujisawa, S., & Yoshida, S. (2002) · Journal of Applied Physics · doi:10.1063/1.1426244 · Cited by 15
Noradrenergic Modulation on Dopaminergic Neurons
Zhu, M. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9889-z · Cited by 15
Mack, J. M., Moura, T. D. M., Lanznaster, D., Bobinski, F., Massari, C. M., Sampaio, T. B., Schmitz, A. E., de Souza, L. F., Walz, R., Tasca, C. I., et al. (2018) · NeuroToxicology · doi:10.1016/j.neuro.2018.03.011 · Cited by 16
Endo, S. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-396456-4.00004-3 · Cited by 15
Michel, P. P., Ruberg, M., & Hirsch, É. C. (2006) · Science s STKE · doi:10.1126/stke.3322006pe19 · Cited by 15
Cheetham, J., Coleman, P. D., & Chow, N. (1997) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(97)00109-x · Cited by 15
A Vulnerable Subtype of Dopaminergic Neurons Drives Early Motor Deficits in Parkinson’s DiseasePreprint
Fushiki, A., Ng, D., Lewis, Z., Yadav, A., Saraiva, T., Hammond, L. A., Wirblich, C., Tasic, B., Menon, V., da Silva, J. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629776 · Cited by 19
Magnetic resonance imaging of the dopamine system in schizophrenia – A scoping review
Schulz, J., Zimmermann, J., Sorg, C., Menegaux, A., & Brandl, F. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.925476 · Cited by 14
“For example, the ventral tegmental area is more difficult to image with neuromelanin MRI than the substantia nigra since it is smaller and contains less neuromelanin (43, 44).”
BackgroundDopamine Receptors and the Treatment of Parkinson’s Disease
Gurevich, E. V., & Gurevich, V. V. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-333-6_18 · Cited by 19
“[69–71].”
Kim, T., Jeon, J., Park, J., Park, Y., Kim, J., Noh, H., Kim, H.-S., & Seo, H. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2020.181 · Cited by 15
“Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and alpha-synuclein deposits in various brain regions (Hirsch et al., 1988, 2003).”
BackgroundDu, Y., Lee, Y. B., & Graves, S. M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108817 · Cited by 15
Ye, P., Fang, Q., Hu, X., Zou, W., Huang, M., Ke, M., Li, Y., Liu, M., Cai, X., Zhang, C., et al. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102530 · Cited by 14
“…clusters exhibit greater susceptibility to damage by stress than others, with a well-known example being that the degeneration of DA neurons in the SNc, but not those in the VTA, is most prominent in the brains of Parkinson ’ s Disease (PD) patients (Damier et al., 1999; Hirsch et al., 1988).”
BackgroundYang, C.-H., Chen, C.-W., Lin, Y.-K., Yeh, Y.-C., Hsu, C.-C., Fan, Y., Yu, I., & Chen, J. (2017) · Journal of The Electrochemical Society · doi:10.1149/2.0901712jes · Cited by 14
Gendron, J., Sauty-Colace, C., Beaume, N., Cartonnet, H., Guégan, J., Ulveling, D., Pardanaud-Glavieux, C., Moszer, I., Cheval, H., & Ravassard, P. (2019) · Scientific Reports · doi:10.1038/s41598-018-37872-1 · Cited by 17
Conditioning Against the Pathology of Parkinson's disease.
Leak, R. K. (2018) · PubMed · Cited by 16
Trends and Issues in Characterizing Early Cognitive Changes in Parkinson’s Disease
Claassen, D. O., & Wylie, S. A. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0312-5 · Cited by 15
Hashido, T., & Saito, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165160 · Cited by 14
Seshadri, A., & Alladi, P. A. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00036-8 · Cited by 13
Tau Tangles in Parkinson’s Disease: A 2-Year Follow-Up Flortaucipir PET Study
Hansen, A. K., Parbo, P., Ismail, R., Østergaard, K., Brooks, D. J., & Borghammer, P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191774 · Cited by 17
Dopamine melanin‐loaded PC12 cells: a model for studies on pigmented neurons
Östergren, A., Svensson, A., Lindquist, N. G., & Brittebo, E. B. (2005) · Pigment Cell Research · doi:10.1111/j.1600-0749.2005.00239.x · Cited by 14
Melanized nigral neuronal numbers in Nigerian and British individuals
Muthane, U. B., Chickabasaviah, Y. T., Henderson, J. M., et al. (2006) · Movement Disorders · doi:10.1002/mds.20917 · Cited by 14
Synthetic neuromelanin is toxic to dopaminergic cell cultures
Nguyen, A., Gille, G., Moldzio, R., Hung, S.-T., & Rausch, W. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200054 · Cited by 17
“In both PD and normal aging, these pigmented neurons are most susceptible to death (Hirsch et al., 1988).”
BackgroundVillares, J., Strada, O., Faucheux, B. A., Javoy-Agid, F., Agid, Y., & Hirsch, É. C. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90205-4 · Cited by 14
Self-citation
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.